William Strohl, PhD
BiStro Biotech Consulting
Dr. Bill Strohl has over 35 years of experience in academic and biopharmaceutical research. Prior to starting BiStro Biotech Consulting in 2016, Dr. Strohl was VP and Head, Janssen BioTherapeutics, Janssen R&D. In that role he oversaw biologics discovery, early development, and technology development for the organization and served as a member of the Janssen R&D Senior Leadership Team. Prior to joining Centocor in 2008, Bill led Biologics Discovery efforts for Merck and Co., and was involved in the acquisition of two biotechnology companies and multiple licenses to improve discovery capabilities. Bill now has roles on two Scientific Advisory Boards and one Board of Directors of biotechnology companies.
Anthony Tolcher, MD
Dr. Anthony Tolcher is a medical oncologist and key opinion leader in the field of developing and running early-stage clinical trials for oncology indications. As a co-founder of both NEXT-Oncology and South Texas Accelerated Research Therapeutics (START), clinical research organizations focused on first-in-human clinical trials, he is dedicated to the development of new anti-cancer agents for patients for whom current cancer therapies are no longer working.
Louis M. Weiner, MD
Georgetown Lombardi Comprehensive Cancer Center
Dr. Louis Weiner is the Director of the NCI-designated Georgetown Lombardi Comprehensive Cancer Center. He holds the Francis L. and Charlotte G. Gragnani Chair and is professor of oncology and chair of the Department of Oncology at Georgetown University Medical Center. He is responsible for the operation and development of the cancer center, including its research, clinical and educational missions. Dr. Weiner is recognized for his laboratory and clinical research focusing on new therapeutic approaches that mobilize the patient’s immune system to fight cancer using monoclonal antibodies and other modalities of therapy. He was the recipient of the 2019 American Association Cancer Research (AACR) Distinguished Public Service Award. His current research focuses on identifying and therapeutically exploiting mechanisms employed by malignant cells to combat immune destruction.